TB-500 in South Asian Patients: Safety Profile Differences and Pharmacogenomic Considerations
Evidence-based analysis of TB-500 (thymosin beta-4 active fragment) safety differences in South Asian populations, covering pharmacogenomics, cardiovascular risk modifiers, dosing considerations, and monitoring protocols.
Read clinical review